The favorable prognostic role of elevated PATZ1 expression in lung cancer was confirmed in an independent TCGA mRNA cohort of 994 lung cancer patients (494 LUSCs; 500 LUADs) via the Human Protein Atlas platform [41], in which the 5-year survival was 48% for the high PATZ1 group and 34% for the low PATZ1 group (p < 0.0001) (Figure S1). This evidence concerns the gene PATZ1 and lung carcinoma.